AstraZeneca: acquires Neogene Therapeutics
(CercleFinance.com) - AstraZeneca has announced that it has signed an agreement to acquire Neogene Therapeutics, a clinical-stage biotechnology company pioneering the discovery, development and manufacture of next-generation T-cell receptor (TCR-T) therapies.
This therapy offers a new cell therapy approach to targeting cancer.
With a common goal of bringing cell-based therapies to patients with solid tumours, Neogene's expertise in the discovery, development and manufacture of TCR-Ts will reinforce AstraZeneca's ambition to transform patient outcomes, it said.
TCR-Ts are emerging as a promising therapeutic modality for the treatment of cancer. The TCR-T can recognise intracellular targets, including cancer-specific mutations, potentially unlocking targets previously inaccessible with cell-based therapies.
AstraZeneca said that Neogene's advanced TCR discovery capabilities and extensive manufacturing experience complement the cell therapy capability that it has built over the past three years, enabling the group to accelerate the development of potentially curative cell therapies for the benefit of patients.
Copyright (c) 2022 CercleFinance.com. All rights reserved.